However, it is important to know that a beneficial decrease of the inflammatory state presents when the severity of the disease is at a point where the patient is classified as severe (CRP levels of 120–160 mg/L), excluding the mild, moderate, and even critical patients from the use of tocilizumab due to the counterproductive effects of the drug during these specific stages of COVID-19 where the IL-6 has an anti-inflammatory role (6). The gene discussed is CRP; the disease is COVID-19.